Your browser doesn't support javascript.
loading
COVID-19 booster dose antibody response in pregnant, lactating, and nonpregnant women
Caroline Atyeo PhD; Lydia L Shook MD; Nadege Nziza PhD; Elizabeth A DeRiso PhD; Cordelia Muir; Arantxa Medina Baez; Rosiane S Lima; Stepan Demidkin; Sara Brigida; Rose M De Guzman PhD; Madeleine D Burns; Alejandro B Balazs PhD; Alessio Fasano MD; Lael M Yonker MD; Kathryn J Gray MD PhD; Galit Alter PhD; Andrea G Edlow MD MSc.
Afiliação
  • Caroline Atyeo PhD; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA; PhD Program in Virology, Division of Medical Sciences, Harvard University, Boston, MA, USA
  • Lydia L Shook MD; Department of Obstetrics & Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Vincent Center for Reproductive Biology, Massach
  • Nadege Nziza PhD; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA
  • Elizabeth A DeRiso PhD; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA
  • Cordelia Muir; Department of Obstetrics & Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
  • Arantxa Medina Baez; Department of Obstetrics & Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
  • Rosiane S Lima; Department of Pediatrics, Massachusetts General Hospital, Harvard Medical School, Boston, MA
  • Stepan Demidkin; Department of Obstetrics & Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Vincent Center for Reproductive Biology, Massach
  • Sara Brigida; Department of Obstetrics & Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Vincent Center for Reproductive Biology, Massach
  • Rose M De Guzman PhD; Department of Obstetrics & Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Vincent Center for Reproductive Biology, Massach
  • Madeleine D Burns; Department of Obstetrics & Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Department of Pediatrics, Massachusetts General
  • Alejandro B Balazs PhD; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA
  • Alessio Fasano MD; Department of Pediatrics, Massachusetts General Hospital, Harvard Medical School, Boston, MA
  • Lael M Yonker MD; Department of Pediatrics, Massachusetts General Hospital, Harvard Medical School, Boston, MA
  • Kathryn J Gray MD PhD; Department of Obstetrics and Gynecology, Brigham and Womens Hospital, Harvard Medical School, Boston, MA, USA
  • Galit Alter PhD; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA
  • Andrea G Edlow MD MSc; Department of Obstetrics & Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Vincent Center for Reproductive Biology, Massach
Preprint em En | PREPRINT-MEDRXIV | ID: ppmedrxiv-22275154
ABSTRACT
BACKGROUNDWhile emerging data during the SARS-CoV-2 pandemic have demonstrated robust mRNA vaccine-induced immunogenicity across populations, including pregnant and lactating individuals, the rapid waning of vaccine-induced immunity and the emergence of variants of concern motivated the use of mRNA vaccine booster doses. Whether all populations, including pregnant and lactating individuals, will mount a comparable response to a booster dose is not known. OBJECTIVEWe sought to profile the humoral immune response to a COVID-19 mRNA booster dose in a cohort of pregnant, lactating, and age-matched nonpregnant women. STUDY DESIGNWe characterized the antibody response against ancestral Spike and Omicron in a cohort of 31 pregnant, 12 lactating and 20 nonpregnant age-matched controls who received a BNT162b2 or mRNA-1273 booster dose after primary COVID-19 vaccination. We also examined the vaccine-induced antibody profiles of 15 maternalcord dyads at delivery. RESULTSReceipt of a booster dose during pregnancy resulted in increased IgG1 against Omicron Spike (post-primary vaccination vs post-booster, p = 0.03). Pregnant and lactating individuals exhibited equivalent Spike-specific total IgG1, IgM and IgA levels and neutralizing titers against Omicron compared to nonpregnant women. Subtle differences in Fc-receptor binding and antibody subclass profiles were observed in the immune response to a booster dose in pregnant compared to nonpregnant individuals. Analysis of maternal and cord antibody profiles at delivery demonstrated equivalent total Spike-specific IgG1 in maternal and cord blood, yet higher Spike-specific Fc{gamma}R3a-binding antibodies in the cord relative to maternal blood (p = 0.002), consistent with preferential transfer of highly functional IgG. Spike-specific IgG1 levels in the cord were positively correlated with time elapsed since receipt of the booster dose (Spearman R 0.574, p = 0.035). CONCLUSIONSThese data suggest that receipt of a booster dose during pregnancy induces a robust Spike-specific humoral immune response, including against Omicron. If boosting occurs in the third trimester, higher Spike-specific cord IgG1 levels are achieved with greater time elapsed between receipt of the booster and delivery. Receipt of a booster dose has the potential to augment maternal and neonatal immunity.
Licença
cc_no
Texto completo
Adicionar na Minha BVS
Imprimir
XML
Buscar no Google
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-MEDRXIV Tipo de estudo: Cohort_studies / Observational_studies / Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Preprint
Texto completo
Adicionar na Minha BVS
Imprimir
XML
Buscar no Google
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-MEDRXIV Tipo de estudo: Cohort_studies / Observational_studies / Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Preprint